Fingerprint
Dive into the research topics of 'Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies
Robert J. Kreitman, David R. Squires, Maryalice Stetler-Stevenson, Pierre Noel, David J.P. FitzGerald, Wyndham H. Wilson, Ira Pastan
Research output: Contribution to journal › Article › peer-review
233
Scopus
citations